Lexpos News

Following representations from Community Pharmacy England, the Department of Health and Social Care (DHSC) has re-determined that the following products will be granted special container status from 1 April 2026. Generic drug name (dm+d descriptor) Brand and/or manufacturer Pack Size Special container Afatinib 20mg tablets Giotrif® 20mg tablets (Boehringer Ingelheim Ltd) 28 tablet        [...]

The post 13 products re-classified as special containers from April 2026 appeared first on Community Pharmacy England.

The Drug Tariff Preface published monthly, lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 April 2026. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item requiring reconstitution [...]

The post Drug Tariff Watch – April 2026 appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Apixaban 2.5mg and 5mg tablets (Sandoz Limited) Drug alert number: EL(26)A/17 Date issued: 26 March 2026 Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information. DMRC reference number: DMRC-38614094 Marketing Authorisation Holder: Sandoz Limited Medicine Details Product [...]

The post MHRA Class 4 Medicines Defect Notification: Apixaban 2.5mg and 5mg tablets (Sandoz Limited) appeared first on Community Pharmacy England.

NHS England has issued an operational briefing via its regions to all pharmacies and general practices providing an update on the Meningococcal disease outbreak in Kent and announcing the waiving of NHS prescription charges for prophylactic oral Ciprofloxacin prescriptions issued to patients in relation to the outbreak. Prescribers in general practices have been asked to [...]

The post Free supply extended to Ciprofloxacin for meningococcal outbreak appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Vesomni 6 mg/0.4 mg modified release tablets (Quadrant Pharmaceuticals Limited) Drug alert number: EL(26)A/16 Date issued: 26 March 2026 Quadrant Pharmaceuticals Limited have informed the MHRA that their parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton. DMRC [...]

The post MHRA Class 4 Medicines Defect Notification: Vesomni 6 mg/0.4 mg modified release tablets (Quadrant Pharmaceuticals Limited) appeared first on Community Pharmacy England.